RHYTHM PHARMACEUTICALS, INC. Cost of Revenue
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Cost of Revenue of $8.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $8.93M, a 61.12% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $7.16M, a 96.19% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $4.80M, a 26.80% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $5.50M, a 43.65% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $19.49M, a 45.81% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $13.37M, a 43.71% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $9.30M, a 336.10% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $2.13M, a 256.09% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.93M 10-Q · filed 2026-08-04 | $16.09M 10-Q · filed 2026-08-04 | $20.89M derived: sum of 3 quarters · filed 2026-08-04 | $26.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.16M 10-Q · filed 2026-05-05 | $11.96M derived: sum of 2 quarters · filed 2026-05-05 | $17.46M derived: sum of 3 quarters · filed 2026-05-05 | $23.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.30M derived: sum of 2 quarters · filed 2026-02-26 | $15.84M derived: sum of 3 quarters · filed 2026-08-04 | $19.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.50M 10-Q · filed 2025-11-04 | $11.04M derived: sum of 2 quarters · filed 2026-08-04 | $14.69M 10-Q · filed 2025-11-04 | $18.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.54M 10-Q · filed 2026-08-04 | $9.19M 10-Q · filed 2026-08-04 | $12.98M derived: sum of 3 quarters · filed 2026-08-04 | $16.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.65M 10-Q · filed 2026-05-05 | $7.43M derived: sum of 2 quarters · filed 2026-05-05 | $11.26M derived: sum of 3 quarters · filed 2026-05-05 | $14.21M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.62M derived: sum of 2 quarters · filed 2026-02-26 | $10.56M derived: sum of 3 quarters · filed 2026-02-26 | $13.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.83M 10-Q · filed 2025-11-04 | $6.78M derived: sum of 2 quarters · filed 2025-11-04 | $9.58M 10-Q · filed 2025-11-04 | $12.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.95M 10-Q · filed 2025-08-05 | $5.75M 10-Q · filed 2025-08-05 | $8.99M derived: sum of 3 quarters · filed 2026-02-26 | $11.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.81M 10-Q · filed 2025-05-07 | $6.04M derived: sum of 2 quarters · filed 2026-02-26 | $8.45M derived: sum of 3 quarters · filed 2026-02-26 | $10.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.64M derived: sum of 2 quarters · filed 2026-02-26 | $7.88M derived: sum of 3 quarters · filed 2026-02-26 | $9.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.41M 10-Q · filed 2024-11-06 | $4.65M derived: sum of 2 quarters · filed 2024-11-06 | $6.07M 10-Q · filed 2024-11-06 | $7.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $2.24M 10-Q · filed 2024-08-06 | $3.66M 10-Q · filed 2024-08-06 | $4.68M derived: sum of 3 quarters · filed 2025-02-28 | $5.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.42M 10-Q · filed 2024-05-07 | $2.45M derived: sum of 2 quarters · filed 2025-02-28 | $2.95M derived: sum of 3 quarters · filed 2025-02-28 | $3.32M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.52M derived: sum of 2 quarters · filed 2025-02-28 | $1.90M derived: sum of 3 quarters · filed 2025-02-28 | $2.13M 10-K · filed 2025-02-28 |
| 2022-09-30 | $497.00K 10-Q · filed 2023-11-08 | $875.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.10M 10-Q · filed 2023-11-08 | $1.34M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $378.00K 10-Q · filed 2023-08-01 | $608.00K 10-Q · filed 2023-08-01 | $844.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.07M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $230.00K 10-Q · filed 2023-05-02 | $466.00K derived: sum of 2 quarters · filed 2024-02-29 | $688.00K derived: sum of 3 quarters · filed 2024-02-29 | $825.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $458.00K derived: sum of 2 quarters · filed 2024-02-29 | $595.00K derived: sum of 3 quarters · filed 2024-02-29 | $599.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $222.00K 10-Q · filed 2022-11-08 | $359.00K derived: sum of 2 quarters · filed 2022-11-08 | $363.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $137.00K 10-Q · filed 2022-08-03 | $141.00K 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |